Milestone reached in the clinical development of TG-1801 (NI-1701)

Global collaboration with TG Therapeutic (NSDAQ: TGTX).

GENEVA, SWITZERLAND/ MAY 18, 2021 /

Light Chain Bioscience | Novimmune SA announced today that under its global collaboration agreement with TG Therapeutics (NSDAQ: TGTX) a predefined milestone was reached in the clinical development of TG-1801 (NI-1701), a bispecific antibody targeting CD19 and CD47.

“We are excited with the progress of TG-1801 in the current Phase I clinical trial in Australia by our partner TG Therapeutics, as well as the recent approval of an IND and start of Phase I in the US. TG-1801 is the first bispecific antibody allowing for selective CD47 targeting on tumor cells, a unique mechanism of action that we are deploying in other internal and partnered bispecific programs for the treatment of cancer” said Nicolas Fischer CEO of Light Chain Bioscience. “The clinical progress of TG-1801 brings further validation to our bispecific kappa-lambda body format that maintains the native structure of a human IgG.”

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.